Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$2.34
-$0.01(-0.99%)
At close: 4:00 PM EDT
$2.34
-$0.01(-0.99%)
Day’s Range― - ―
52-Week Range$1.09 - $2.76
Previous CloseN/A
Volume110.63K
Average Volume (3M)5.22M
Market Cap
$292.07M
Enterprise Value$83.52M
Total Cash (Recent Filing)$172.80M
Total Debt (Recent Filing)$32.76M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 10, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding111,656,920
10 Day Avg. Volume4,025,570
30 Day Avg. Volume5,216,042
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue6.02
Enterprise Value/Gross Profit6.02
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$3.90Price Target Upside66.67% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$12.57M
Bulls Say, Bears Say
Bulls Say
Genentech PartnershipThe Genentech agreement validates a lead program while transferring development, regulatory, manufacturing, and commercialization responsibilities to a larger partner. The upfront payment and potential milestone and royalty economics can support Alector’s pipeline while reducing execution demands on its own resources.
Funding RunwayThe equity financing provides additional resources for research and development, working capital, and other corporate needs. Although it increases the share count, the proceeds improve near-term funding visibility for advancing the neurodegeneration pipeline and proprietary ABC platform.
Specialized PipelineA concentrated focus on immune and inflammatory mechanisms gives Alector a defined scientific strategy across Alzheimer’s disease, frontotemporal dementia, and related disorders. This specialization may support cumulative platform knowledge and multiple development opportunities over time.
Bears Say
Heavy Cash BurnSustained cash outflows of this magnitude indicate that operations and development activities are not self-funding. Continued investment in clinical programs will therefore require substantial external financing, partnering proceeds, or asset monetization, leaving less flexibility if funding conditions or milestones change.
Negative EquityNegative stockholders’ equity signals weakened financial flexibility and makes the balance sheet less resilient to additional losses. Combined with declining assets, this condition can constrain capital allocation and increase reliance on new financing or strategic transactions to sustain development.
Deteriorating ProfitabilityThe combination of contracting revenue, very large losses, and a negative gross-profit result shows that the current earnings model remains highly unstable. Without a clear path to profitability in the provided results, future progress depends heavily on successful development and partnering outcomes.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $1.09 and its highest was $2.76 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $292.07M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Aug 06, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.229 by $0.019.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.22.
How many shares outstanding does Alector Inc have?
Alector Inc has 111,656,920 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.229. Following the earnings report the stock price went down -2.732%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.90 (66.67% Upside)
$3.90 (66.67% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 46.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $284.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.48%
12-Months-Change
Fundamentals
Return on Equity
-531.04%
Trailing 12-Months
Asset Growth
-43.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alector Inc
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
ALEC Stock 12 Month Forecast
Average Price Target
$3.90
▲(66.67% Upside)
Technical Analysis
Ownership Overview
7.45% Insiders
11.57% Mutual Funds
39.72% Other Institutional Investors
32.33% Public Companies and
Individual Investors